Substance / Medication

Methenamine

Overview

Active Ingredient
methenamine
RxNorm CUI
6832

Indications

Uretron D/S tablets are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

Labeler: DORAL PHARMAMEDICS INC dba A.G. Marin PharmaceuticalsUpdated: 2025-12-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Use of Methenamine for Urinary Tract Infection Prophylaxis: Systematic Review of Recent Evidence.
Davidson Spencer M, Brown Jamie N, Nance Clayton B et al. · Int Urogynecol J · 2024
PMID: 38329493Meta-Analysis
Methenamine for urinary tract infection prophylaxis: A systematic review.
Li Jian Mei, Cosler Leon E, Harausz Elizabeth P et al. · Pharmacotherapy · 2024
PMID: 37986168Meta-Analysis
The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women- a systematic review.
Kale Saurabh, Somani Bhaskar K · Curr Opin Urol · 2023
PMID: 37337660Meta-Analysis
Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis.
Bakhit Mina, Krzyzaniak Natalia, Hilder Joanne et al. · Br J Gen Pract · 2021
PMID: 34001538Meta-AnalysisFull text (PMC)
Methenamine hippurate for preventing urinary tract infections.
Lee Bon San B, Bhuta Tushar, Simpson Judy M et al. · Cochrane Database Syst Rev · 2012
PMID: 23076896Meta-AnalysisFull text (PMC)
Methenamine hippurate for preventing urinary tract infections.
Lee B B, Simpson J M, Craig J C et al. · Cochrane Database Syst Rev · 2007
PMID: 17943785Meta-Analysis
Methenamine hippurate for preventing urinary tract infections.
Lee B, Bhuta T, Craig J et al. · Cochrane Database Syst Rev · 2002
PMID: 11869659Meta-Analysis
Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women-a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU).
Heltveit-Olsen Silje Rebekka, Arnljots Egill Snaebjörnsson, Sundvall Pär-Daniel et al. · Clin Microbiol Infect · 2025
PMID: 40669691RCT
Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study.
Neto Felício Savioli, Hachul Helena, Pereira Márcio Antônio et al. · Int Urogynecol J · 2023
PMID: 37851092RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methenamine (substance)
SNOMED CT
372773008
UMLS CUI
C0025638
RxNorm CUI
6832
Labeler
DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.